Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014038 | 1.00 | GPR119 (0.38) | GPR119ESR2PIP5K1CNR1H2MGLL | |
| SCHEMBL24913918 | 1.00 | GPR119 (0.38) | GPR119ESR2PIP5K1CNR1H2MGLL | |
| SCHEMBL31014101 | 0.93 | MGLL (0.40) | GPR119PIP5K1CMGLLABHD6ALDH1A1 | |
| SCHEMBL31013948 | 0.93 | MGLL (0.40) | GPR119PIP5K1CMGLLABHD6ALDH1A1 | |
| SCHEMBL31013911 | 0.90 | GPR119 (0.41) | GPR119ESR2NR1H2MGLLABHD6 | |
| SCHEMBL31014086 | 0.89 | PIP5K1C (0.39) | PIP5K1CMGLLABHD6PRMT5WDR77 | |
| SCHEMBL29168685 | 0.89 | PIP5K1C (0.39) | PIP5K1CMGLLABHD6PRMT5WDR77 | |
| SCHEMBL29168681 | 0.89 | PIP5K1C (0.39) | PIP5K1CMGLLABHD6PRMT5WDR77 | |
| SCHEMBL31013866 | 0.87 | ALDH1A1 (0.43) | ESR2NR1H2ALDH1A1HRH3 | |
| SCHEMBL24913887 | 0.86 | GPR119 (0.38) | GPR119ESR2NR1H2ALDH1A1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | GPR119 2087/4885ESR2 568/4885PIP5K1C 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.